Corbus Pharmaceuticals
CRBP
81 hedge funds and large institutions have $111M invested in Corbus Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 15 closing their positions.
277% more call options, than puts
Call options by funds: $6.38M | Put options by funds: $1.69M
78% more capital invested
Capital invested by funds: $62.5M → $111M (+$48.8M)
1% more funds holding
Funds holding: 80 → 81 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
2.25% less ownership
Funds ownership: 74.06% → 71.81% (-2.2%)
29% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$1.1M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$812K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$786K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$662K |
| 5 |
SCM
Superstring Capital Management
New York
|
+$548K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$2.25M |
| 2 |
BlackRock
New York
|
-$1.19M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$651K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$470K |
| 5 |
EAM
Exome Asset Management
New York
|
-$450K |
CRBP Hedge Fund Activity: Q3 2025 in Review
81 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2025, worth a combined $111M — up 78% from $62.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CRBP positions and 15 closed out — a net gain of 1 holder — while 17 added to existing stakes and 24 trimmed.
The largest buyer was Aberdeen Group, adding an estimated $1.1M. The largest seller was Prosight Management, cutting an estimated $2.25M.
- 81 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2025, up from 80 in Q2 2025.
- Funds reported $111M of Corbus Pharmaceuticals stock for Q3 2025, up 78% quarter-over-quarter.
- 16 funds opened new Corbus Pharmaceuticals positions in Q3 2025 and 15 closed out, a net change of +1 holder.
- The largest Corbus Pharmaceuticals buyer in Q3 2025 was Aberdeen Group, an estimated $1.1M added.
- The largest Corbus Pharmaceuticals seller in Q3 2025 was Prosight Management, an estimated $2.25M sold.
Based on aggregated 13F filings for Q3 2025.